Diabetes drug may shield hepatitis b patients from liver failure

NCT ID NCT06364930

Recruiting now Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This 5-year study tests whether dapagliflozin, a diabetes drug, can prevent serious liver complications in people with chronic hepatitis B and diabetes who already have early liver scarring. 412 participants will receive either dapagliflozin or a placebo daily. The goal is to see if the drug reduces the risk of liver cancer, fluid buildup, bleeding, or other liver-related events.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Dapagliflozin
What this could lead to: If it works, this could show that dapagliflozin reduces the risk of serious liver problems like liver cancer or fluid buildup in people with hepatitis B and diabetes.
What could go wrong: This is a Phase 4 trial, so dapagliflozin is already approved for diabetes, but its benefit for liver complications is unproven. The 5-year study may not show a clear effect, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic hepatitis B virus infection hepatitis B virus infection type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC HEPATITIS B

Contacts and locations

Locations

Prince of Wales Hospital
RECRUITING

Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.